



PATENT
Attorney Docket No. 043B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : DUNMORE, S. J. <i>et al.</i>	Art Unit : 1649
Serial No. : 10/753,717	Examiner : HAYES, Robert C.
Filed : January 8, 2004	
Title : INHIBITION OF AMYLIN RELEASE	

Commissioner of Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

TERMINAL DISCLAIMER UNDER 37 C.F.R. §3.73(b)
AND § 1.321(b)

Dear Sir,

I hereby certify under 37 CFR 1.10
that this correspondence is being
deposited with the United States
Postal Service as Express mail
EV954532885 US

with sufficient postage on the date
indicated below and is addressed to
the Commissioner of Patents, PO
Box 1450, Alexandria, VA 22313-
1450.

Date of Deposit April 20, 2007

Dawn M MacPherson

Dawn M MacPherson

Pursuant to 37 C.F.R. §3.73(b), Société de Conseils de Recherches et d'Applications Scientifiques, S.A.S., a corporation duly organized under the corporate laws of France, hereby certifies that it is the Assignee of the entire right, title, and interest in the above application by virtue of:

☒ A chain of title from the inventors of the patent application identified above to the current Assignee as shown below:

1. As above captioned U.S. Patent Application Serial No. 10/753,717 is a divisional application of U.S. Application Serial No. 08/961,968 filed on October 31, 1997, and

2. As U.S. Application Serial No. 08/961,968 is a divisional application of U.S. Application Serial No. 08/440,061 filed on May 12, 1995, now issued as U.S. Patent No. 5,763,200, and

04/23/2007 SSITHIB1 00000017 500590 10753717

01 FC:1814 130.00 DA

3. Michael Anthony Cawthorne, Michelle Davenport and Simon Jon Dunmore assigned U.S. Application Serial No. 08/440,061 filed on May 12, 1995, now issued as U.S. Patent No. 5,763,200, to the University of Buckingham, Buckingham, United Kingdom. The document was recorded in the U. S. Patent and Trademark Office at Reel 9312, Frame 0497 on July 13, 1998; a copy is enclosed herewith.

2. The University of Buckingham assigned U.S. Application Serial No. 08/440,061 filed on May 12, 1995, now issued as U.S. Patent No. 5,763,200, to Société de Conseils de Recherches et d'Applications Scientifiques, S.A.S. The document was recorded in the U. S. Patent and Trademark Office at Reel 014175, Frame 0092 on December 3, 2003; a copy is enclosed herewith.

Société de Conseils de Recherches et d'Applications Scientifiques, S.A.S., also hereby certifies that it is the Assignee of the entire right, title, and interest in U.S. Patent Application 08/440,061 now issued as U.S. Patent No. 5,763,200 by virtue of:

A chain of title from the inventors of U.S. Patent Application Serial No. 08/440,061 now issued as U.S. Patent No. 5,763,200 to the current Assignee as shown below:

1. From Michael Anthony Cawthorne, Michelle Davenport and Simon Jon Dunmore to the University of Buckingham, Buckingham, United Kingdom. The document was recorded in the Patent and Trademark Office at Reel 9312, Frame 0497 on July 13, 1998.

2. From the University of Buckingham to Société de Conseils de Recherches et d'Applications Scientifiques, S.A.S. The document was recorded in the Patent and Trademark Office at Reel 014175, Frame 0092 on December 3, 2003.

The undersigned has reviewed all the documents in the chain of title of the above-identified applications and, to the best of undersigned's knowledge and belief, title to both is in the Assignee identified above.

Pursuant to 37 C.F.R. § 1.321(b), and to obviate a nonstatutory obviousness-type double patenting rejection, the Assignee identified above hereby waives and disclaims the terminal portion of the term of the entire patent to be granted upon the above identified application subsequent to the expiration of U.S. Patent No. 5,763,200. Further, any patent granted on the above identified application shall be enforceable only for and during such period that it is commonly owned with U.S. Patent No. U.S. Patent No. 5,763,200.

The Assignee identified above does not disclaim any terminal part of any patent granted on the above identified application prior to the expiration date of the full statutory terms of any patents granted upon U.S. Patent No. 5,763,200 in the event that any related patent later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of their statutory term, except for the separation of legal title as stated above.

This disclaimer runs with any patent granted on the above application and U.S. Patent No. 5,763,200 and is binding upon the grantee, its successors or assigns.


Enclosed is authorization to charge for the required fee pursuant to 37 C.F.R. § 1.20(d).

Inventor : Dunmore *et al.*
Serial No. : 10/753,717
Filed : January 8, 2004
Page : 4

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,
IPSEN (BIOMEASURE)

Date: 4/20/2007



Alan F. Feeney
Attorney for Applicant(s)
Reg. No. 43,609

Biomeasure, Inc.
27 Maple Street
Milford, MA 01757-3650
Phone (508) 478-0144
Fax (508) 473-3531